NXG Investment Management’s Aerie Pharmaceuticals AERI Stock Holding History

NXG Investment Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-68,869	Closed	-$785K	–	125
2021 Q3	$785K	Buy	68,869 +1,382	+2%	+$20.2K	0.08%	81
2021 Q2	$1.08M	Sell	67,487 -749	-1%	-$12.8K	0.1%	78
2021 Q1	$1.22M	Buy	68,236 +48,166	+240%	+$832K	0.14%	68
2020 Q4	$271K	Sell	20,070 -27,620	-58%	-$334K	0.03%	117
2020 Q3	$561K	Buy	47,690 +3,536	+8%	+$43.1K	0.08%	79
2020 Q2	$652K	Buy	44,154 +9,962	+29%	+$147K	0.07%	83
2020 Q1	$462K	Buy	+34,192	New	+$649K	0.07%	77

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

NXG Investment Management's AERI Position: Q4 2021 in Review

NXG Investment Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 68,869 shares — an estimated $785K sold.

NXG Investment Management first reported a position in AERI in Q1 2020 and held it in 7 quarters. The position peaked at $1.22M in Q1 2021. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

NXG Investment Management reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
NXG Investment Management sold 68,869 Aerie Pharmaceuticals shares in Q4 2021, an estimated $785K.
NXG Investment Management first reported a position in Aerie Pharmaceuticals in Q1 2020 and held it in 7 quarters.
NXG Investment Management's Aerie Pharmaceuticals position peaked at $1.22M in Q1 2021.
129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on NXG Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.